1294 related articles for article (PubMed ID: 28326566)
1. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
[TBL] [Abstract][Full Text] [Related]
4. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
Danese S; Fiorino G; Peyrin-Biroulet L; Lucenteforte E; Virgili G; Moja L; Bonovas S
Ann Intern Med; 2014 May; 160(10):704-11. PubMed ID: 24842416
[TBL] [Abstract][Full Text] [Related]
5. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.
Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
Aliment Pharmacol Ther; 2014 Apr; 39(7):660-71. PubMed ID: 24506179
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
12. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
13. Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease.
Hunter T; Komocsar WJ; Colletti RB; Liu C; Benkov KJ; Dotson JL; Steiner SJ; Zhang N; Crandall W;
Curr Med Res Opin; 2023 Jan; 39(1):63-69. PubMed ID: 36263735
[TBL] [Abstract][Full Text] [Related]
14. Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy.
Farkas K; Lakatos PL; Szűcs M; Pallagi-Kunstár É; Bálint A; Nagy F; Szepes Z; Vass N; Kiss LS; Wittmann T; Molnár T
World J Gastroenterol; 2014 Mar; 20(11):2995-3001. PubMed ID: 24659890
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
16. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
Williams CJ; Peyrin-Biroulet L; Ford AC
Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV
Mayo Clin Proc; 2014 Dec; 89(12):1621-35. PubMed ID: 25441399
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Molnár T
Expert Opin Biol Ther; 2015; 15(9):1257-62. PubMed ID: 26134250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
